Mr. Alejandro Antalich reports

EVOKAI CREATIVE LABS ANNOUNCES TRADING ON THE OTCQB(R) AND DTC ELIGIBILITY AS PART OF ITS MARKET EXPANSION

EvokAI Creative Labs Inc.'s common shares will commence trading on the OTCQB Venture Market in the United States at the market open on July 21, 2023, under the symbol OKAIF.

EvokAI Creative Labs announces trading on the OTCQB and DTC eligibility as part of its market expansion

"Admission to the OTCQB market is part of EvokAI's strategy to introduce the company to a more comprehensive international audience," said Alejandro Antalich, chief executive officer of EvokAI. "Listing on the OTCQB provides EvokAI with increased visibility among the United States investment community and increased liquidity for our current and prospective shareholders."

Additionally, the company has received eligibility for book-entry delivery and depository services of the Depository Trust Corp. (DTC), to facilitate electronic settlement of transfers of its common shares in the United States. This electronic method of clearing securities expedites the receipt of stock and cash and accelerates the settlement process for investors. DTC eligibility enhances the company's potential investor base and offers a more convenient trading experience for current and future shareholders while enhancing the liquidity of the company's common shares on the OTCQB.

The OTCQB Venture Market is a premiere marketplace for developing U.S. and international companies that are committed to providing a high-quality trading and information experience for their United States investors. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. Investors can find real-time Level 2 quotes and market information on the OTC Markets website.

EvokAI also continues to trade on the TSX Venture Exchange (TSX-V) under its existing symbol OKAI.

About EvokAI Creative Labs Inc.

EvokAI is a medical technology artificial intelligence-powered company dedicated to the development of transformational and innovative technologies for the modern health care sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole health care system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.

We seek Safe Harbor.